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ACE inhibitorAbstract Background: Angiotensin I-converting enzyme (ACE) has two homologous catalytic
domains, theN- andC-domains.Our previous study suggested thatAlu insertion (I allele) in the intron
16 of ACE resulted in premature codon termination. The I allele has only one active site in the N-
domain while the Alu deletion (D allele) still has two active sites of ACE. Therefore the effect of I/
D polymorphism of ACE on the enzyme’s ability to catalyse bradykinin is still not widely known.
Aims: This study aimed to examine the serum bradykinin level in hypertensive patients with I/D
polymorphism of ACE, who were treated with ACE inhibitor.
Subjects and methods: The serum bradykinin and I/D polymorphism have been detected in 64
hypertensive patients taking ACE inhibitor (lisinopril or captopril) for at least eight weeks with good
medicationadherence.ThebindingaffinityofACEwith its receptorwas calculatedbymolecular dock-
ing.
Results: The findings show that genotype II is more frequent in the population the researchers
observed (53.12%) compared to ID (23.44%) andDD (23.44%) variances.On the other hand, the bra-
dykinin level is not affected by genotype of the ACE genes on the population. Bradykinin increases inalang,
188 Widodo et al.patients with genotype II who are given captopril, but decreases in patients treated with lisinopril.
Nevertheless, there is no statistically significant difference.
Conclusion: This study suggests that thepolymorphismmightnot significantly affect the serumbra-
dykinin level in hypertensive patients taking ACE inhibitors.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Angiotensin I-converting enzyme (ACE) is a zinc metallopep-
tidase that plays an important role in blood pressure regula-
tion [1–3]. The ACE has two homologous catalytic domains,
the N- and C-domains, which are able to cleave angiotensin
I and bradykinin [4,5,2]. The C-domain of ACE is more effi-
cient in cleaving angiotensin I into vasopressor angiotensin
II [4]. However, reports regarding the bradykinin binding site
to the ACE are still limited. This information is necessary to
measure the strength of binding competition between bradyki-
nin and the angiotensin I to the ACE, although the ACE inhi-
bitors generally have a higher affinity for the bradykinin than
the angiotensin I binding sites [5]. This knowledge is essential
for developing more specific ACE inhibitors on angiotensin I
binding site as a hypertension drug that has no side effects
on cough.
Our previous study suggested that Alu insertion (I) in the
intron 16 of ACE resulted in premature codon termination,
so the protein has only one active site in the N-domain while
the Alu deletion allele (D) still has two active sites. The
meta-analysis indicated that the D allele is related to higher
levels of angiotensinogen that is associated with metabolic syn-
drome [6], while the I allele of ACE correlated with the devel-
opment of Alzheimer’s disease [7]. Moreover, the I/D
polymorphism in the ACE gene has been linked to several
kinds of diseases, such as coronary artery disease [8], infections
in post-operative cardiac valve surgery patients [9] and arterial
hypertension [10].
Therefore information of the effect I/D polymorphism on
ACE activity in catalysing bradykinin is still limited. Further,
we have examined the serum bradykinin level in hypertensive
patients with I/D polymorphism of ACE, who were treated
with ACE inhibitor. This study suggests that the polymor-
phism does not significantly influence the serum bradykinin
level of hypertensive patients who are taking ACE inhibitors.
2. Subjects and methods
2.1. Subjects and detection of serum bradykinin level
The study recruited 64 hypertensive patients, over 18 years old,
who had been taking an ACE inhibitor (lisinopril or captopril)
for at least eight weeks with good medication adherence, mea-
sured by the Morisky Medication Adherence Scale (MMAS).
Patients with secondary hypertension, cardiovascular diseases,
liver dysfunction, and were currently receiving treatment with
angiotensin receptor blockers (ARBs) were excluded from this
study. A blood sample was taken to detect ACE polymor-
phism and measure bradykinin level. The level of bradykinin
serum was measured according to the manufacturer’s instruc-
tions (Cusabio Biotech; Cat. No. CSB-E09155h), the levels ofbradykinin serum were examined using Analysis of Variance
and quantitative variables were expressed as mean ± standard
deviation values. A value of p 6 0.05 was considered as statis-
tically significant. This study has followed the Code of Ethics
of the world Medical Association (Declaration of Helsinki)
for experiments in humans and approved by Brawijaya
University/RSSA hospital ethics.
2.2. Polymorphism detection
Genomic DNA samples were isolated by DNA extraction kit
(GeneaidTM). Then the genomic DNA was used as a template
to amplify a DNA fragment on intron 16 of the ACE gene.
The amplification was done by polymerase chain reaction
(PCR), using a forward primer 50-GCC CTG CAG GTG
TCT GCA GCA TGT-30 and reverse 50-GGA TGG CTC
TCC CCG CCT TGT CTC-30. Thirty-four cycles of PCR were
performed with the following parameters: denaturation at
96 C for 45 s, annealing at 60.3 C for 45 s, and extension at
72 C for 45 s. The D allele is characterised by a 312-bp frag-
ment, whereas 599-bp fragment indicates I allele. Each sample
found to have the DD genotype was subjected to the second
PCR to amplify a region inside intron 16 with insertion-
specific primers 50-TGG GAC CAC AGC GCC CGC CAC
TAC-30 and 50-TCG CCA GCC CTC CCA TGC CCA
TAA-30 to avoid ID-DD mistyping [9].
2.3. Molecular docking
The ACE molecule was retrieved from Protein Data Bank in
Europe (PDBe) with access code 5AMB [11]. The simplified
molecular input line entry system (SMILES) structure of bra-
dykinin and angiotensin I was taken from PubChem [12], then
they were converted into PDB format using Discovery Studio
Software [13]. Lisinopril and the N-domain of ACE were
extracted from PDB (2C6N) [14], while captopril and the C-
domain of ACE were retrieved from PDB (1UZF) [15]. Molec-
ular docking between ACE and its ligands (lisinopril, capto-
pril, bradykinin and angiotensin I) were performed by using
AutoDock Vina, PyRx software [16]. The predicted binding
affinity (kcal/mol) was calculated by AutoDock Vina. All
molecules were visualised by Discovery Studio [13].
3. Results
3.1. Interaction of ACE with bradykinin and angiotensin I
ACE has two domains – the N- and C-terminals [3–5]. Both
domains work independently and alternately when they catal-
yse their substrates [17]. ACE with Alu insertion (I) in the
intron 16 was predicted to lose the C-domain, while the Dele-
tion allele(D) still has two active sites [18]. Furthermore, dock-
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Figure 1 The interaction between ACE and its substrates. The full-length structure of ACE, which has two domains (N- and C-domains)
(5AMB), Alu element insertion (I allele) might induce premature termination that results in the loss of the C-domain (A). Bradykinin and
angiotensin I have the same binding site in both the N- and C-domains (B). Bradykinin has an equal binding affinity in both the N- and C-
domains, but angiotensin I looks more strong binding in the N-domain rather than in the C-domain (C).
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-6.1 Captorpil -5.9
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The binding aﬃnity between ACE and its inhibitor 
Figure 2 Binding Position between ACE and its inhibitors.
Captopril (yellow) and lisinopril (Green) bind with ACE (N- and
C-domains) (A); It is predicted that captopril binds as strongly in
both domains while lisinopril tends to have a stronger binding in
C-domain (B).
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N- and C-domains with their substrates, bradykinin and
angiotensin I. The result of the analysis shows that bradykinin
has a similar binding affinity towards the N- and C-domains of
ACE (Fig. 1). This is in line with the previous study, which
states that the bradykinin level is equivalent in the N-domain
or C-domain of mice [3]. Conversely, angiotensin I has a smal-
ler binding affinity towards the N-terminal compared to C-
terminal.
Furthermore, we analysed the binding affinity of the N- and
C-domains of ACE with captopril or lisinopril. The study
examined the inhibitors’ preference to block ACE activities.
The binding affinity is essential to determine the potency of
the inhibitor in controlling the variation of ACE (ID) activityin order to catalyse bradykinin. Analysis using molecular dock-
ing shows that captopril has a similar binding affinity in both
domains, which indicates captopril is efficient in binding to both
domains. However, lisinopril has a smaller binding affinity in the
C-domain than in the N-domain. This means lisinopril binds
more efficiently in the C-domain. Both molecules are attached
to the active side of the two ACE domains (Fig. 2).
3.2. Correlation between genotype of ACE and serum bradykinin
level
The baseline characteristics of hypertensive patients from two
groups – patients who were treated with lisinopril and patients
who were treated with captopril – showed no significant differ-
ences. The measured characteristics were age, sex, Systolic
Blood Pressure (SBP; mmHg), Diastolic Blood Pressure
(DBP; mmHg), blood glucose and cholesterol. Among the 64
hypertension patients, 34 were found to have genotype II,
and 30 patients had DD/DI genotype.
We have measured the level of serum bradykinin of 64
hypertensive patients who were treated with an ACE inhibitor,
either captopril or lisinopril. The findings show that ACE II
variance is found more frequently in the population
(53.12%) compared to DI (23.44%) and DD (23.44%) vari-
ance (Table 1).
On the other hand, the level of bradykinin is barely influ-
enced by the genotype of the ACE genes. Even though the level
of bradykinin increases in genotype II of the patients treated
using captopril, its level decreases in patients treated with lisino-
pril. However, there is no statistically significant difference.
4. Discussion
Angiotensin-converting enzyme (ACE) is an enzyme that plays
a crucial role in controlling blood pressure by the cleavage of
Table 1 The serum bradykinin level (pg/ml) in patients receiving lisinopril and captopril.
ACE inhibitor ACE genotype P-value
DD DI II
Captopril 4.12 ± 3.03 (n= 7) 4.30 ± 3.00 (n= 8) 6.47 ± 5.65 (n= 17) 0.40
Lisinopril 5.59 ± 4.02 (n= 8) 5.87 ± 2.01 (n= 7) 4.79 ± 4.53 (n= 17) 0.88
*p value 6 0.05 = significantly different between groups; n= number of subject.
190 Widodo et al.angiotensin I into angiotensin II, which triggers vasoconstric-
tion. In addition, ACE also inactivates bradykinin, a substance
of the function of which is to increase vasodilatation in the
body. Thus, ACE works simultaneously to catalyse angioten-
sin I and bradykinin [2,3]. ACE has two independent catalytic
domains [3–5]. The domains are capable of cleaving angioten-
sin I and bradykinin but differ in binding affinity [14]. The
results of the docking analysis show that the binding affinity
of angiotensin I to the N-domain is stronger to the C-
domain, while the binding affinity of bradykinin is almost
equal to both the N- and C-domain. Moreover, the binding
affinity of ACE to bradykinin is stronger than that of angio-
tensin I. It can be concluded that ACE more preferably binds
to bradykinin than angiotensin I, therefore, the inhibition of
the bradykinin binding site on ACE is a promising target for
developing antihypertension drugs. These data correspond
with the previous study that demonstrated that ACE inhibitor
has a higher binding affinity towards bradykinin than it has
towards angiotensin I binding site [5]. Hence, ACE is the pri-
mary target for drugs used to control hypertension [19].
ACE gene variance due to insertion or deletion of Alu ele-
ments is predicted to have an influence on bradykinin catalysis.
Further analysis shows that bradykinin binds equally strongly
to the N- and C-domains of ACE. The data indicate that both
ACE domains have a similar quality in bradykinin catalysis.
This is in line with the previous study that found that deletion
on either the N- or C-domain of ACE does not affect the level
of bradykinin in the mice [3]. Thus, the ability of ACE to
inactivate bradykinin is not affected by insertion or deletion.
This is supported by the study that found that the bradykinin
level in the serum of genotype II and DD does not show a sig-
nificant difference. This is consistent with other studies in
Japanese hypertensive patients receiving an ACE inhibitor
[17,18].
Although ACE genetic variance does not influence the level
of bradykinin significantly, the bradykinin level tends to be
affected by ACE inhibitor therapy used by patients. ACE inhi-
bitor reduces the ACE activity that may lead to the accumula-
tion of serum bradykinin. The level of bradykinin tends to
increase in patients treated with captopril and, conversely, to
decrease in patients treated using lisinopril, even though statis-
tically there was no significant difference. This condition might
be caused by the large standard deviation as a result of the low
sample number. Therefore, adequate samples are needed to
analyse the statistical significance of ACE gene I/D variant
with the level of bradykinin serum.
The phenomenon indicated that ACE inhibitor influenced
serum bradykinin levels. This can be seen from the binding
affinity between captopril and lisinopril in each ACE domain.
Lisinopril has a higher binding affinity for the C-domain
of ACE, which indicates that lisinopril inhibits the C-domain
of ACE more efficiently than the N-domain. These datacorrespond with in vitro data that show that the inhibitory con-
stant (Ki) of lisinopril is lower in the C-domain than in the N-
domain [20]. This phenomenon is supported by our serum bra-
dykinin level data. The serum bradykinin level in hypertensive
patients with ID/DD genotype receiving lisinopril tended to be
higher than in those with II genotype, although the difference
is not statistically significant. Captopril was bound to N- and
C-domains with similar affinity. The data are analogous to a
previous study that found that captopril has a similar binding
affinity in the two domains [21]. This result means that capto-
pril could bind into the two ACE domains, but its inhibitory
potency is higher in the N-domain than in the C-domain.
Interestingly, the level of bradykinin serum in patients receiv-
ing captopril was greater in the II genotype than in the DD
genotype. Because I allele might have only the N-domain, cap-
topril could bind effectively, so the I variant showed a slightly
higher serum bradykinin serum level than the D allele.5. Conclusion
The binding affinity of bradykinin was equal in both the C-and
N-domains of ACE. There was no statistical difference in the
level of bradykinin in the II and DD genotype of a hyperten-
sive patient treated with ACE inhibitor, captopril or lisinopril.
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